Entrada Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
TRDA$5.25+11.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Income (Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Collaboration revenue | $25,421 | $210,782 |
| Operating expenses: | ||
| Research and development | 142,269 | 125,306 |
| General and administrative | 41,050 | 38,465 |
| Total operating expenses | 183,319 | 163,771 |
| (Loss) income from operations | (157,898) | 47,011 |
| Other income: | ||
| Interest and other income | 15,072 | 19,474 |
| Total other income | 15,072 | 19,474 |
| (Loss) income before provision for income taxes | (142,826) | 66,485 |
| Provision for income taxes | 924 | 859 |
| Net (loss) income | $(143,750) | $65,626 |
| Net (loss) income per share, basic | $(3.47) | $1.76 |
| Net (loss) income per share, diluted | $(3.47) | $1.68 |
| Weighted‑average common shares outstanding, basic | 41,371,486 | 37,306,363 |
| Weighted‑average common shares outstanding, diluted | 41,371,486 | 39,003,169 |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities, net of tax of $0 | 695 | (238) |
| Total other comprehensive income (loss) | 695 | (238) |
| Total comprehensive (loss) income | $(143,055) | $65,388 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.